Nonsevere Hypoglycemia Episode Clinical and Economic Outcomes: A Comparison between Sulfonylurea and Sodium-Glucose Cotransporter 2 Inhibitor as Add-On to Metformin from a Canadian Perspective

Table 4

Estimated costs secondary to excess NSHEs due to SU utilization versus SGLT2i after metformin.

Scenarios (probability of single episode per patient per year)	Outcome in CDN$ for 2016
	Base	Minimum	Maximum
Total indirect costs including work productivity and out of pocket	8.6M	5.3M	81.2M
Out-of-pocket costs	1.8M	1.1M	16.9M
Lost work productivity	6.8M	4.2M	64.3M
NSHE and self-treated (only direct cost)	1.4M	0.9M	6.9M

Base scenario assumptions: included only patients between 20 and 65; incorporated average income loss and costs; have not incorporated underreporting for NSHEs in real-world clinical settings. Minimum scenario assumptions: included only patients between 20 and 65; incorporated average minimum income loss and costs; have not incorporated underreporting for NSHEs in real-world clinical settings. Maximum scenario assumptions: included all patients; incorporated highest income loss and costs; incorporated underreporting for NSHEs in real-world clinical settings.